
|Videos|July 23, 2021
First Vyluma product tackles pediatric myopia
Advertisement
Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2025: A real-world assessment of dry eye relief in habitual drop users
2
AAOpt 2025: The lost art of corneal GP fitting for regular corneas
3
Takeaways from this week in optometry: October 20 - October 24
4
FDA sends CRL to Sydnexis for SYD-101 to slow myopia in children
5

















































.png)


